Cefazolin as second line treatment for invasive Methicillin-Susceptible Staphylococcus aureus infection in a UK cohort of patients.

Young, Bernadette C; Dunsmure, Louise; Downs, Louise; Kildonaviciute, Kornelija; Jones, Nicola

Young, Bernadette C; Dunsmure, Louise; Downs, Louise; Kildonaviciute, Kornelija; Jones, Nicola.

Affiliation

Young BC; Microbiology and Infectious Diseases Department, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom; Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Dunsmure L; Antimicrobial Pharmacy, Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Downs L; Microbiology and Infectious Diseases Department, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Kildonaviciute K; Antimicrobial Pharmacy, Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Jones N; Microbiology and Infectious Diseases Department, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom. Electronic address: Nicola.jones@ouh.nhs.uk.

J Infect ; 82(5): e25-e27, 2021 05.

Article in En | MEDLINE | ID: mdl-33548357

Subject(s)
Key words

Cefazolin; Staphylococcus aureus

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Staphylococcal Infections / Cefazolin Type of study: Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: J Infect Year: 2021 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google